XTLB
XTL Biopharmaceuticals Ltd.
Biotechnology
Market Cap$294K
5Y Perf.-50.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
XTLB vs AVXL
Revenue, margins, valuation, and 5-year total return — side by side.
AVXL
Anavex Life Sciences Corp.
Biotechnology
Market Cap$289M
5Y Perf.-24.1%
XTLB vs AVXL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | XTLB | AVXL |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $294K | $289M |
| Revenue (TTM) | $451K | $0.00 |
| Net Income (TTM) | $-1M | $-40M |
| Gross Margin | 26.4% | — |
| Operating Margin | -481.6% | — |
| Total Debt | $138K | $0.00 |
| Cash & Equiv. | $371K | $103M |
XTLB vs AVXL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
XTLB
AVXL
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| XTL Biopharmaceutic… (XTLB) | 100 | 49.8 | -50.2% |
| Anavex Life Science… (AVXL) | 100 | 75.9 | -24.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: XTLB vs AVXL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: AVXL leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. XTL Biopharmaceuticals Ltd. is the stronger pick specifically for recent price momentum and sentiment and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
XTLB
XTL Biopharmaceuticals Ltd.
The Growth Play
XTLB is the clearest fit if your priority is growth exposure.
- EPS growth 45.5%
- -50.9% vs AVXL's -63.2%
- -17.7% ROA vs AVXL's -30.0%
Best for: growth exposure
AVXL
Anavex Life Sciences Corp.
The Income Pick
AVXL carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.51
- -25.7% 10Y total return vs XTLB's -87.3%
- Lower volatility, beta 1.51, current ratio 11.60x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | AVXL | -34.9% revenue growth vs XTLB's -173.2% |
| Quality / Margins | AVXL | 4.5% margin vs XTLB's -227.7% |
| Stability / Safety | AVXL | Beta 1.51 vs XTLB's 1.71 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | XTLB | -50.9% vs AVXL's -63.2% |
| Efficiency (ROA) | XTLB | -17.7% ROA vs AVXL's -30.0% |
XTLB vs AVXL — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLXTLBLAGGINGAVXL
AVXLAnavex Life Sciences …
1leads
XTLBXTL Biopharmaceutical…
1leads
6 Total Categories
CATEGORYLEADERvs AVXLMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
AVXL1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
XTLB4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
AVXL leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
XTLB and AVXL operate at a comparable scale, with $451,000 and $0 in trailing revenue.
| Metric | XTLBXTL Biopharmaceut… | AVXLAnavex Life Scien… |
|---|---|---|
| RevenueTrailing 12 months | $451,000 | $0 |
| EBITDAEarnings before interest/tax | -$1M | -$30M |
| Net IncomeAfter-tax profit | -$1M | -$40M |
| Free Cash FlowCash after capex | $0 | -$34M |
| Gross MarginGross profit ÷ Revenue | +26.4% | — |
| Operating MarginEBIT ÷ Revenue | -4.8% | — |
| Net MarginNet income ÷ Revenue | -2.3% | — |
| FCF MarginFCF ÷ Revenue | -3.7% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +20.0% | +54.4% |
AVXL leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — XTLB and AVXL each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | XTLBXTL Biopharmaceut… | AVXLAnavex Life Scien… |
|---|---|---|
| Market CapShares × price | $293,767 | $289M |
| Enterprise ValueMkt cap + debt − cash | $60,767 | $187M |
| Trailing P/EPrice ÷ TTM EPS | -0.28x | -5.78x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.65x | — |
| Price / BookPrice ÷ Book value/share | 0.05x | 2.81x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — XTLB and AVXL each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
Evenly matched — XTLB and AVXL each lead in 3 of 6 comparable metrics.
Profitability & Efficiency
XTLB delivers a -25.5% return on equity — every $100 of shareholder capital generates $-26 in annual profit, vs $-32 for AVXL. On the Piotroski fundamental quality scale (0–9), XTLB scores 3/9 vs AVXL's 2/9, reflecting mixed financial health.
| Metric | XTLBXTL Biopharmaceut… | AVXLAnavex Life Scien… |
|---|---|---|
| ROE (TTM)Return on equity | -25.5% | -31.5% |
| ROA (TTM)Return on assets | -17.7% | -30.0% |
| ROICReturn on invested capital | -54.1% | — |
| ROCEReturn on capital employed | -50.7% | -47.8% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 |
| Debt / EquityFinancial leverage | 0.03x | — |
| Net DebtTotal debt minus cash | -$233,000 | -$103M |
| Cash & Equiv.Liquid assets | $371,000 | $103M |
| Total DebtShort + long-term debt | $138,000 | $0 |
| Interest CoverageEBIT ÷ Interest expense | -13.31x | — |
Evenly matched — XTLB and AVXL each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
XTLB leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AVXL five years ago would be worth $2,759 today (with dividends reinvested), compared to $1,963 for XTLB. Over the past 12 months, XTLB leads with a -50.9% total return vs AVXL's -63.2%. The 3-year compound annual growth rate (CAGR) favors XTLB at -18.4% vs AVXL's -28.1% — a key indicator of consistent wealth creation.
| Metric | XTLBXTL Biopharmaceut… | AVXLAnavex Life Scien… |
|---|---|---|
| YTD ReturnYear-to-date | +11.3% | -15.2% |
| 1-Year ReturnPast 12 months | -50.9% | -63.2% |
| 3-Year ReturnCumulative with dividends | -45.7% | -62.9% |
| 5-Year ReturnCumulative with dividends | -80.4% | -72.4% |
| 10-Year ReturnCumulative with dividends | -87.3% | -25.7% |
| CAGR (3Y)Annualised 3-year return | -18.4% | -28.1% |
XTLB leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — XTLB and AVXL each lead in 1 of 2 comparable metrics.
Risk & Volatility
AVXL is the less volatile stock with a 1.51 beta — it tends to amplify market swings less than XTLB's 1.71 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. XTLB currently trades 26.0% from its 52-week high vs AVXL's 22.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | XTLBXTL Biopharmaceut… | AVXLAnavex Life Scien… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.71x | 1.51x |
| 52-Week HighHighest price in past year | $10.28 | $13.99 |
| 52-Week LowLowest price in past year | $1.05 | $2.61 |
| % of 52W HighCurrent price vs 52-week peak | +26.0% | +22.3% |
| RSI (14)Momentum oscillator 0–100 | 57.0 | 47.0 |
| Avg Volume (50D)Average daily shares traded | 2.4M | 1.4M |
Evenly matched — XTLB and AVXL each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | XTLBXTL Biopharmaceut… | AVXLAnavex Life Scien… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $11.00 |
| # AnalystsCovering analysts | — | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
AVXL leads in 1 of 6 categories (Income & Cash Flow). XTLB leads in 1 (Total Returns). 3 tied.
Best OverallXTL Biopharmaceuticals Ltd. (XTLB)Leads 1 of 6 categories
Loading custom metrics...
XTLB vs AVXL: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is XTLB or AVXL a better buy right now?
Analysts rate Anavex Life Sciences Corp.
(AVXL) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — XTLB or AVXL?
Over the past 5 years, Anavex Life Sciences Corp.
(AVXL) delivered a total return of -72. 4%, compared to -80. 4% for XTL Biopharmaceuticals Ltd. (XTLB). Over 10 years, the gap is even starker: AVXL returned -25. 7% versus XTLB's -87. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — XTLB or AVXL?
By beta (market sensitivity over 5 years), Anavex Life Sciences Corp.
(AVXL) is the lower-risk stock at 1. 51β versus XTL Biopharmaceuticals Ltd. 's 1. 71β — meaning XTLB is approximately 13% more volatile than AVXL relative to the S&P 500.
04Which has better profit margins — XTLB or AVXL?
Anavex Life Sciences Corp.
(AVXL) is the more profitable company, earning 0. 0% net margin versus -227. 7% for XTL Biopharmaceuticals Ltd. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AVXL leads at 0. 0% versus -481. 6% for XTLB. At the gross margin level — before operating expenses — XTLB leads at 0. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — XTLB or AVXL?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is XTLB or AVXL better for a retirement portfolio?
For long-horizon retirement investors, Anavex Life Sciences Corp.
(AVXL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. XTL Biopharmaceuticals Ltd. (XTLB) carries a higher beta of 1. 71 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AVXL: -25. 7%, XTLB: -87. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between XTLB and AVXL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.